Join the DDA or

New naltrexone/bupropion driving warning

August drug safety update published

August 22nd 2019

Tagged: Clinical guidance news

By Ailsa Colquhoun

The August 2019 issue of Drug Safety Update is available online.

Among the new advice is a warning about the medicine naltrexone/bupropion (Mysimbaâ–¼), authorised for the management of weight in obese adults and in overweight adults with one or more weight-related conditions. Naltrexone/bupropion has been associated with adverse reactions such as dizziness or somnolence, and patients should be advised not to drive if they suspect their ability may be impaired.

The drug’s Patient Information Leaflet will be an important basis for this discussion with patients.

For all the latest news of the 2020 DDA annual conference...

Learn more